Imatinib Aurovitas

Imatinib, the active ingredient in Imatinib Aurovitas, is a tyrosine kinase inhibitor presented as a tablet for oral use. It targets specific cellular enzymes that drive the growth of certain cancers and is prescribed for patients with chronic myeloid leukemia, Philadelphia‑positive acute lymphoblastic leukemia, gastrointestinal stromal tumours, and other approved indications.

GNH USA supplies Imatinib Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable logistics for global distribution.

Imatinib is a BCR‑ABL tyrosine kinase inhibitor used in several oncologic indications.

- Chronic Myeloid Leukemia (CML): achieves disease control and prolongs survival. - Philadelphia‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): induces remission in eligible patients. - Gastrointestinal Stromal Tumor (GIST): reduces tumor size and delays progression. - Dermatofibrosarcoma Protuberans (DFSP): provides disease control after surgical resection. - Systemic Mastocytosis: alleviates symptoms and reduces mast cell burden.

Imatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Muscle cramps: intermittent skeletal muscle discomfort. - Fatigue: generalized tiredness. - Diarrhea: loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Neutropenia: significant reduction in white blood cells, increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury requiring monitoring. - Cardiac failure: signs of reduced cardiac function, such as dyspnea or edema.

Before initiating Imatinib, clinicians should evaluate several safety parameters and follow specific handling guidelines.

- Blood Count Monitoring: perform baseline and regular CBC to detect cytopenias. - Liver Function Assessment: check hepatic enzymes before treatment and periodically thereafter. - Cardiac Evaluation: assess baseline cardiac function in patients with pre‑existing heart disease. - Hypersensitivity Screening: avoid use in individuals with known allergy to imatinib or its excipients. - Pregnancy and Lactation: weigh potential risks; use only if benefits justify exposure. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels and risk adverse effects. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower drug exposure and reduce efficacy. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, requiring close INR monitoring.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam, tacrolimus): imatinib may increase their concentrations. - Diuretics (e.g., furosemide): may potentiate fluid retention and edema. - Live vaccines: immunosuppression may reduce vaccine efficacy; consider timing.